On 25 September 2017, SIX Swiss Exchange listed biopharmaceutical company Newron Pharmaceuticals S.p.A. ("Newron") headquartered in Bresso/Milan, Italy and focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system announced that it had successfully raised gross proceeds of approximately CHF 27.0 million following a private placement. By way of an accelerated bookbuilding after market close, Newron shares were placed with investors both in Europe and the US (pursuant to an applicable exemption from the registration requirements of the US Securities Act of 1933, as amended).

Niederer Kraft & Frey AG acted as Swiss counsel to Newron. The NKF team included partners Thomas Brönnimann and Philippe Weber, along with senior associate Christina Del Vecchio.